English (UK)
中文版Fosun 
Fosun Hani Securities Limited is a wholly-owned subsidiary of Fosun International Limited (HKEx: 00656), a leading global investment group (Fosun Group).
Fosun Hani Securities is Fosun Group's integrated financial hub and primary investment arm in Hong Kong. Established in 1995, Fosun Hani Securities is a participant member of The Stock Exchange of Hong Kong Limited (Broker No. 0820 and 0829).
Fosun Hani Securities is Fosun Group's integrated financial hub and primary investment arm in Hong Kong. Established in 1995, Fosun Hani Securities is a participant member of The Stock Exchange of Hong Kong Limited (Broker No. 0820 and 0829).
Joe Lai
Managing DirectorFosun Pharma
Fosunpharma is a leading healthcare group in China. It has built a strong root domestically and developed a global operation strategy. With pharmaceutical manufacturing and R&D being core business segment, together with strong presences in medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail.
Scarlett Shen
Investment managerGalixir
Founded in 2019, Galixir aspires to be an engine to fuel up the whole pharmaceutical industry leveraging its world-leading AI technologies.
We have a team with solid background in both AI and pharmaceutical science. Our core team members come from MIT, Yale, Johns Hopkins, THU, PKU and other top universities, as well as leading pharma and tech companies.
We have a team with solid background in both AI and pharmaceutical science. Our core team members come from MIT, Yale, Johns Hopkins, THU, PKU and other top universities, as well as leading pharma and tech companies.
Justin Qin
Strategy and Business Development VPGan&Lee Pharmaceuticals
Founded in 1998, Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China.
晓婷 郑
BD高级经理Geneception Inc.
Geneception is an innovation-driven biopharmaceutical company focusing on gene and cell therapy medicines.
Dr. Amber Cai
CEOGenetron Health
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.
Responsive Web Design powered by 